Selective anti-Toxoplasma gondii activities of azasterols

被引:33
作者
Dantas-Leite, L
Urbina, JA
de Souza, W
Vommaro, RC
机构
[1] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Lab Ultraestructura Celular Hertha Meyer, BR-21949900 Rio De Janeiro, Brazil
[2] Inst Venezolano Invest Cient, Lab Quim Biol, Ctr Biofis & Bioquim, Caracas 1020A, Venezuela
关键词
azasterols; T gondii; mitochrondrial activity; ultrastructure;
D O I
10.1016/j.ijantimicag.2003.11.005
中图分类号
R51 [传染病];
学科分类号
100401 [流行病与卫生统计学];
摘要
We report potent and selective inhibitory effects of 22,26-azasterol and 24,25-(R,S)-epiminolanosterol, known inhibitors of Delta(24(25))-sterol methyltranferase (SMT) in fungi and protozoa, on the proliferation of Toxoplasma gondii in LLCMK2 cells. These compounds produced a dose-dependent reduction in parasite proliferation. 22,26-azasterol had an IC50 of 5.3 muM after 24 It and 4.5 muM after 48 h, while for 24,25-(R,S)-epiminolanosterol the IC50 values were I muM after 24 It and 0.12 muM after 48 h. The rapid reduction of parasite load suggested these compounds have selective cytotoxic effects against T gondii. However, we were unable to detect 24-alkyl sterols in purified T gondii tachyzoites using highly sensitive gas-liquid chromatography/mass spectrometry methods, a fact which indicated that the anti-proliferative effects of these azasterols were not mediated by inhibition of SMT. Transmission electron microscopy showed that the mitochondrion was the major target of drugs. Ultrastructural effects on plasma membrane, apicoplast and the formation of autophagosomal structures were also observed. (C) 2004 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:620 / 626
页数:7
相关论文
共 22 条
[1]
ALDER J, 1994, J ACQ IMMUN DEF SYND, V7, P1141
[2]
The molecular basis of sulfonamide resistance in Toxoplasma gondii and implications for the clinical management of toxoplasmosis [J].
Aspinall, TV ;
Joynson, DHM ;
Guy, E ;
Hyde, JE ;
Sims, PFG .
JOURNAL OF INFECTIOUS DISEASES, 2002, 185 (11) :1637-1643
[3]
Toxoplasma gondii exploits host low-density lipoprotein receptor-mediated endocytosis for cholesterol acquisition [J].
Coppens, I ;
Sinai, AP ;
Joiner, KA .
JOURNAL OF CELL BIOLOGY, 2000, 149 (01) :167-180
[4]
Structures of Toxoplasma gondii tachyzoites, bradyzoites, and sporozoites and biology and development of tissue cysts [J].
Dubey, JP ;
Lindsay, DS ;
Speer, CA .
CLINICAL MICROBIOLOGY REVIEWS, 1998, 11 (02) :267-+
[5]
LIPIDS AND FATTY-ACIDS OF TACHYZOITES AND PURIFIED PELLICLES OF TOXOPLASMA-GONDII [J].
FOUSSARD, F ;
GALLOIS, Y ;
GIRAULT, A ;
MENEZ, JF .
PARASITOLOGY RESEARCH, 1991, 77 (06) :475-477
[6]
ASSESSMENT OF THERAPY FOR TOXOPLASMA ENCEPHALITIS - THE TE STUDY-GROUP [J].
HAVERKOS, HW .
AMERICAN JOURNAL OF MEDICINE, 1987, 82 (05) :907-914
[7]
JORGE TCD, 1984, ACTA TROP, V41, P17
[8]
Lüder CGK, 2001, TRENDS PARASITOL, V17, P480, DOI [10.1016/S1471-4922(01)02016-5, 10.1016/S1471-4922(01)02093-1]
[9]
TOXOPLASMIC ENCEPHALITIS IN AIDS [J].
LUFT, BJ ;
REMINGTON, JS .
CLINICAL INFECTIOUS DISEASES, 1992, 15 (02) :211-222
[10]
NEW MICROMETHOD TO STUDY THE EFFECT OF ANTIMICROBIAL AGENTS ON TOXOPLASMA-GONDII - COMPARISON OF SULFADOXINE AND SULFADIAZINE INDIVIDUALLY AND IN COMBINATION WITH PYRIMETHAMINE AND STUDY OF CLINDAMYCIN, METRONIDAZOLE, AND CYCLOSPORIN-A [J].
MACK, DG ;
MCLEOD, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1984, 26 (01) :26-30